Philadelphia, PA – According to filings with the U.S. Securities and Exchange Commission, Scout Bio is raising $33,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Heffernan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Scout Bio
Scouts mission is to harness the genetic revolution transforming human medicine to deliver the future of veterinary medicine. By combining world-leading talent in animal health and gene therapy technology, we have built a development platform for one-time therapies that address major areas of unmet medical need in pet medicine. We are a global company supported by leading life sciences investors and an R&D collaboration with the renowned Gene Therapy Program at the University of Pennsylvania. About Our Currently Enrolling Study for Cats. Scouts first therapy in development focuses on the anemia associated with chronic kidney disease (CKD) in cats. Our study is currently enrolling cats at participating clinics across the U.S. It involves a single injection (followed by 70 days of monitoring) and may relieve a cats anemia for life.

To learn more about Scout Bio, visit http://www.scoutbio.co/

Contact:
Mark Heffernan, Chief Executive Officer
267-244-8159
mark.heffernan@scoutbio.co
https://www.linkedin.com/in/maheffernan/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved